secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-12-20T23:59:59+00:00
Accession:  0001326190-22-000016
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports positive 24-week pemvidutide NAFLD trial: >75% liver fat reduction, 7.2% weight loss at 1.8 mg
--------------------------------------------------------------------------------

- At 1.8 mg dose, mean relative liver fat reduction 75.2%; 53.8% achieved normalization (≤5% LFC).
- Mean weight loss of 7.2% (placebo-adjusted 6.0%) in non-diabetic subjects at 1.8 mg dose.
- Significant ALT declines: ≥17 IU/L reduction in subjects with baseline ALT ≥30 IU/L across all doses.
- cT1 response (≥80 ms reduction) achieved in 75% (1.8 mg) and 100% (2.4 mg) of evaluated subjects.
- Pemvidutide well tolerated; 3 serious/severe AEs unrelated to drug; no significant ALT elevations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619022000016/0001326190-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619022000016/alt-20221220x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer